Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...

In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...

💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells. 👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio

The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...

What gets you excited? In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture www.youtube.com/shorts/zQDQq...

Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."

🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪

Inside the AI transformation of drug discovery. On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com #GITEXGlobal #GITEX2025 #TechBio

Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells. Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵

In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵

We♥️our innovators. Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com. At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵

Maintaining our sense of urgency, because patients are waiting. In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio

A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...

“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones 👉 event.webcasts.com/viewer/event...

A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment. 👉 www.ft.com/content/9a8a...

🌄 The peak is now the basecamp. A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...

In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan outlines the strategy for building a #TechBio company that’s positioned to win. 👉 Read more: www.occam-global.com/blogs/an-int...

🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social), Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell 👉Read more: insights.citeline.com/in-vivo/lead...

📣 The inaugural episode of TechBio Talks is now live! Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare. ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: youtube.com/playlist?lis...

🔹 Join us in September as Recursion executives present at two upcoming investor conferences: ▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference ▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference 👉 Learn more and tune in here: ir.recursion.com. #investor #IR #IRconference

🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now: ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: www.youtube.com/playlist?lis...

🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.

🚀 Expanding access to data to accelerate #AI drug discovery. A new article from @britabelli.bsky.social in Future Medicine AI looks at the critical role open datasets play in driving discoveries & initiatives underway to enable more access. www.fmai-hub.com/how-open-dat... #TechBio #drugdiscovery

An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...

In a new series called "Explain the Impact," Chase Neumann, Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify biomarkers that can better guide patient selection and improve outcomes. www.youtube.com/shorts/33ltb...

💡 “It’s not a taller ladder, it’s an elevator.” In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio

Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...

🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio

In a new paper in @acs.org Infectious Diseases, Recursion scientists look at how #AI & automation are helping to tackle ongoing challenges in global public health by: ▪️ generating hypotheses ▪️ overcoming data scarcity ▪️ streamlining clinical trials Read more: www.recursion.com/news/using-a...

At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social about how we’re addressing the high failure rate in drug discovery using data and AI. 👉 full conversation here: biotechtv.com/post/recursi... #TechBio

Join our (L)earnings Call on Tuesday, August 5. Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST. 👉 Submit questions: forms.gle/ciFX2KbLfkAv... 👉 Read more: ir.recursion.com/news-release...

“How do we tap the potential in these data sets that can truly unlock better trials for patients, reduce timelines, and improve the patient experience?” - Sid Jain, SVP of clinical development and data science at Recursion, in a new article in Clinical Leader. www.clinicalleader.com/doc/clinical...

#ThrowbackThursday: Bold bets, breakthroughs & bottlenecks in #AI drug discovery at #BIO. In June, Recursion chief R&D & chief commercial officer Najat Khan, PhD joined industry leaders to discuss the tangible progress that’s already been made leveraging data & AI-led approaches in drug discovery.

Act boldly, with integrity. In a video for our internal Recursion University (RXU) series, co-founder & CEO Chris Gibson illustrates the importance of one of our core values – act boldly, with integrity. #mindset #culture #RXU 👉 www.youtube.com/shorts/hyfh7...

✨Live from #ICML! Researchers from @valenceai.bsky.social – Recursion’s #AI research engine – had a great time sharing our #ML breakthroughs at ICML last week in posters & presentations. 👉 Keep up with all the latest research at Valence here: www.valencelabs.com

In an industry where over 90% of drug candidates fail, we are relentlessly working to find a better way. A new feature in @wired.com highlights the dedicated drug hunters at Recursion using #AI to find new ways to tackle complex diseases. www.wired.com/story/artifi... 🧪 #TechBio

🚀 How #TechBio is transforming drug discovery with data, AI and compute. Erik Douglas, VP of Product at Recursion, will present onstage at Ai4 happening Aug. 11-13 at the MGM Grand in Las Vegas. ai4.io/vegas/regist... #TechBio #AI #Ai4

Advancing full-stack #AI solutions. Sid Jain, SVP of Clinical Development & Data Science, discussed how Recursion is applying AI & technology to accelerate the discovery & development of new medicines in a webinar with Drug Discovery World. www.ddw-online.com/webinar-how-... #TechBio 🧪

Check out our latest ML advances at #ICML2025! 🔹 We’ll be presenting: 📎 Paper 1: Phenom-2 foundation model 📎 Paper 2: New framework to enhance transcriptomics by distilling knowledge from microscopy images 📎 Workshop: SIM: Scaling Up Interventional Models (sites.google.com/view/sim-icm...)

Recursion today announced the acquisition of full rights to the REV102 program from Rallybio. REV102 is a potential first-in-class oral ENPP1 inhibitor for the rare genetic disorder Hypophosphatasia (HPP). Learn more: ir.recursion.com/news-release...

A new feature in @pharmaphorum.bsky.social gets behind the buzzwords to look at what’s needed – namely, data quality, team culture, and clinical execution – to truly shift to an AI-led approach to developing new #cancer drugs across the industry. 👉 pharmaphorum.com/deep-dive/bu... #TechBio 🧪

🤖 This week, we’re letting the robots take over while the humans recharge during our company-wide summer holiday. See you next week!⛱️ 🌞

🚀 Accelerating Boltz-2 for more efficient structure-based hit discovery. Today, Recursion is open-sourcing its SynFlowNet-Boltz trainer to enable more efficient design of high-affinity binders needed for successful early-stage drug discovery. Learn more: www.recursion.com/news/beyond-... #TechBio 🧪

Why Big Pharma is increasingly working with #TechBio partners. Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD, speaks with Peter Lawson, a biotech analyst at Barclays. 👉 Watch the full webcast here: barclays.webcasts.com/starthere.js...

We had a great turnout for #MoML 2025. Sponsored by Recursion & @valenceai.bsky.social, MoML convenes researchers from academia & industry to discuss how ML can address key scientific goals related to molecular modeling, molecular interactions & therapeutic design. 👉https://portal.ml4dd.com/ 🧪

2 weeks ago, Kelly Zalocusky, Senior Director of Computational Biology, joined a panel at London Tech Week to discuss “AI in Action.” On June 24, she'll present at Discovery & Development Europe on “Unlocking Drug Discovery At Scale Through Lab Automation & AI." oxfordglobal.com/discovery-de...

Recursion cofounder & CEO Chris Gibson sat down with David Bearss, cofounder & CEO of Halia Therapeutics & host of the Good Medicine Podcast, to discuss the original Recursion pitch, the rise of #TechBio, and why he believes a massive sea change is coming soon. 👉 www.youtube.com/watch?v=0LaO...

Recursion has joined the Council for Responsible Use of AI in Clinical Trials, launched today from Advarra, along with leaders from Sanofi and Velocity Clinical Research, Inc., to drive responsible AI innovation in clinical R&D. www.advarra.com/news/advarra... #clinicaltrials 🧪

Last week, Recursion CFO Ben Taylor spoke at the Goldman Sachs 46th Annual Healthcare Conference in Miami, discussing validation points for the Recursion Operating System, pipeline advances, and how we drive value from collaborations like Boltz-2. 👉 event.webcasts.com/viewer/event... #TechBio 🧪

Join us at #BIO25! On Tues., June 17, 1:45-2:45pm ET, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will present on the panel “Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks.” convention.bio.org/program-1/co... #TechBio 🧪